Conexiant
Login
  • JADPRO
  • The ASCO Post
  • JNCCN
JADPRO
  • From the Journal
     
    • Online First

    Issues

    • Current
    • Archive
    • Supplements

    Sections

    • Editorial
    • Research and Scholarship
    • Review Article
    • Grand Rounds
    • Practice Matters
    • Prescriber's Corner
    • Diagnostic Snapshot
    • Meeting Report
    • Meeting Abstracts
  • Topics & Conditions

    Solid Tumors

    • Breast Cancer
    • Central Nervous System Cancers
    • Colorectal Cancer
    • View All

    Hematologic Malignancies

    • Leukemia
    • Multiple Myeloma
    • Myelodysplastic Syndromes
    • View All

    Issues in Oncology

    • Cardio-Oncology
    • Genomics/Genetics
    • Clinical Trial Design
    • View All

    Supportive Care

    • Symptom Management
    • Pain Management
    • Palliative Care
    • View All

    Developmental Therapeutics

    • CAR T-Cell Therapy
    • Immunotherapy
    • View All
  • Events

    Live Events

    • JADPRO Live

    Webinars

    • JADPRO Clinical Case Series JADPRO Best Practices Summit

    Coverage

    • Newsreels
    • Meeting Hightlights
  • Education

    Educational Resources

    • Newsreels
    • Expert Conversations
    • FDA Focus
    • Patient Education
    • Roundtable Series
    • Meeting Highlights
    • Resource Centers
  • Multimedia
    • Podcasts
    • Videos
  • About
Subscribe Submission
Submissions Subscribe
JADPRO / Education / FDA Focus / Revuforj revumenib for relapsed or refractory acute leukemia with a KMT2A translocation

Revuforj (revumenib) for relapsed or refractory acute leukemia with a KMT2A translocation

November 15, 2024

Initial US Approval:

2024

Key Clinical Studies:

SNDX-5613-0700, NCT04065399; AUGMENT-101

Drug Class/Description:

Menin inhibitor

Indications and Usage:

Treatment of relapsed or refractory acute leukemia with a lysine methyltransferase 2A gene (KMT2A) translocation in adult and pediatric patients 1 year and older.

Dosage Administration:

  • Select patients for treatment with REVUFORJ based on the presence of a KMT2A translocation.
  • Administer REVUFORJ orally twice daily fasted or with a low-fat meal at approximately the same time each day.
  • See Full Prescribing Information for recommended REVUFORJ dosage regimen, dosage modifications, and administration instructions.

Dosage Forms and Strengths:

Tablets: 25 mg, 110 mg, 160 mg

Contraindications:

None.

Warnings and Precautions:

QTc Interval Prolongation: Monitor electrocardiograms and electrolytes. Correct hypokalemia and hypomagnesemia prior to and during treatment. If QTc interval prolongation occurs, interrupt, reduce, or permanently discontinue REVUFORJ.

Embryo-Fetal Toxicity: Can cause fetal harm. Advise females of reproductive potential and males with female partners of reproductive potential of potential risk to a fetus and to use effective contraception.

Adverse Reactions:

The most common adverse reactions (≥ 20%) including laboratory abnormalities, are hemorrhage, nausea, phosphate increased, musculoskeletal pain, infection, aspartate aminotransferase increased, febrile neutropenia, alanine aminotransferase increased, parathyroid hormone intact increased, bacterial infection, diarrhea, differentiation syndrome, electrocardiogram QT prolonged, phosphate decreased, triglycerides increased, potassium decreased, decreased appetite, constipation, edema, viral infection, fatigue, and alkaline phosphatase increased.

Use in Specific Populations:

  • Lactation: Advise not to breastfeed

Adapted from:

https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/218944s000lbl.pdf 

Every health-care provider should make their own determination regarding specific safe and appropriate patient care practices, including drug dosages and indications. The provider should always consult the most recent prescribing/product information. FDA Focus information is not guaranteed to be accurate, complete, or current. JADPRO and its editors, authors, reviewers, and commentators cannot be held responsible for any liability incurred as a consequence of the application of any of the information listed within.

More From FDA Focus

Bizengri (zenocutuzumab-Zbco) for non-small cell lung cancer and pancreatic adenocarcinoma

December 04, 2024

Nubeqa (darolutamide) for metastatic castration-sensitive prostate cancer

June 03, 2025

Ziihera (zanidatamab-hrii) for previously treated unresectable or metastatic HER2-positive biliary tract cancer

November 20, 2024

Advertisement
Current Issue
May/Jun 2025 Cover
May/Jun 2025 Cover Art
Vol 16 No 3 May/Jun 2025

Rare Diseases and Educational Tools for Advanced Practitioners

Beth Faiman, PhD, MSN, APRN-BC, AOCN®, BMTCN, FAAN, FAPO

May 15, 2025

A Pilot Program Implementing an Evidence-Based Walking Plan to Improve Cancer-Related Fatigue

Jennifer D. Bernt, DNP, FNP-C, AOCNP, Rita Million, PhD, RN, PHNA-BC, CNE, COI, Nicole S. Pham, MPH Et al.

May 15, 2025

Ductal Carcinoma In Situ Non Mass Enhancement on MRI 10 Years Before Mammographic Microcalcifications

Nancy W. Stead, MD, Andria P. Caton, RN, OCN, CHPN

May 15, 2025

Table of Contents Archive
JADPRO Logo
JADPRO's Facebook Account JADPRO's X Account JADPRO's LinkedIn Account
Submissions Subscribe

About

  • About Us
  • Society
  • Terms and Conditions
  • Privacy Policy
  • Advertise With JADPRO

Membership

  • Login

Conexiant Oncology Publications

  • The ASCO Post
  • JNCCN
  • JNCCN 360

Copyright © 2024 Conexiant unless otherwise noted. All rights reserved. Reproduction in whole or in part without permission is prohibited.